ESCMID*  ||| S:0 E:8 ||| NNP
guideline  ||| S:8 E:18 ||| NN
for  ||| S:18 E:22 ||| IN
the  ||| S:22 E:26 ||| DT
diagnosis  ||| S:26 E:36 ||| NN
and  ||| S:36 E:40 ||| CC
management  ||| S:40 E:51 ||| NN
of  ||| S:51 E:54 ||| IN
Candida  ||| S:54 E:62 ||| NNP
diseases  ||| S:62 E:71 ||| VBD
2012 ||| S:71 E:75 ||| CD
:  ||| S:75 E:77 ||| :
diagnostic  ||| S:77 E:88 ||| JJ
procedures  ||| S:88 E:99 ||| NNS
As  ||| S:99 E:102 ||| IN
the  ||| S:102 E:106 ||| DT
mortality  ||| S:106 E:116 ||| NN
associated  ||| S:116 E:127 ||| VBN
with  ||| S:127 E:132 ||| IN
invasive  ||| S:132 E:141 ||| JJ
Candida  ||| S:141 E:149 ||| JJ
infections  ||| S:149 E:160 ||| NN
remains  ||| S:160 E:168 ||| VBZ
high ||| S:168 E:172 ||| JJ
,  ||| S:172 E:174 ||| ,
it  ||| S:174 E:177 ||| PRP
is  ||| S:177 E:180 ||| VBZ
important  ||| S:180 E:190 ||| JJ
to  ||| S:190 E:193 ||| TO
make  ||| S:193 E:198 ||| VB
optimal  ||| S:198 E:206 ||| JJ
use  ||| S:206 E:210 ||| NN
of  ||| S:210 E:213 ||| IN
available  ||| S:213 E:223 ||| JJ
diagnostic  ||| S:223 E:234 ||| JJ
tools  ||| S:234 E:240 ||| NNS
to  ||| S:240 E:243 ||| TO
initiate  ||| S:243 E:252 ||| VB
antifungal  ||| S:252 E:263 ||| JJ
therapy  ||| S:263 E:271 ||| NN
as  ||| S:271 E:274 ||| IN
early  ||| S:274 E:280 ||| JJ
as  ||| S:280 E:283 ||| IN
possible  ||| S:283 E:292 ||| JJ
and  ||| S:292 E:296 ||| CC
to  ||| S:296 E:299 ||| TO
select  ||| S:299 E:306 ||| VB
the  ||| S:306 E:310 ||| DT
most  ||| S:310 E:315 ||| RBS
appropriate  ||| S:315 E:327 ||| JJ
antifungal  ||| S:327 E:338 ||| JJ
drug ||| S:338 E:342 ||| NN
.  ||| S:342 E:344 ||| .
A  ||| S:344 E:346 ||| DT
panel  ||| S:346 E:352 ||| NN
of  ||| S:352 E:355 ||| IN
experts  ||| S:355 E:363 ||| NNS
of  ||| S:363 E:366 ||| IN
the  ||| S:366 E:370 ||| DT
European  ||| S:370 E:379 ||| NNP
Fungal  ||| S:379 E:386 ||| NNP
Infection  ||| S:386 E:396 ||| NNP
Study  ||| S:396 E:402 ||| NNP
Group  ||| S:402 E:408 ||| NNP
( ||| S:408 E:409 ||| -LRB-
EFISG ||| S:409 E:414 ||| NNP
)  ||| S:414 E:416 ||| -RRB-
of  ||| S:416 E:419 ||| IN
the  ||| S:419 E:423 ||| DT
European  ||| S:423 E:432 ||| NNP
Society  ||| S:432 E:440 ||| NNP
of  ||| S:440 E:443 ||| IN
Clinical  ||| S:443 E:452 ||| NNP
Microbiology  ||| S:452 E:465 ||| NNP
and  ||| S:465 E:469 ||| CC
Infectious  ||| S:469 E:480 ||| NNP
Diseases  ||| S:480 E:489 ||| NNP
( ||| S:489 E:490 ||| -LRB-
ESCMID ||| S:490 E:496 ||| NNP
)  ||| S:496 E:498 ||| -RRB-
undertook  ||| S:498 E:508 ||| VBD
a  ||| S:508 E:510 ||| DT
data  ||| S:510 E:515 ||| NN
review  ||| S:515 E:522 ||| NN
and  ||| S:522 E:526 ||| CC
compiled  ||| S:526 E:535 ||| VBN
guidelines  ||| S:535 E:546 ||| NNS
for  ||| S:546 E:550 ||| IN
the  ||| S:550 E:554 ||| DT
clinical  ||| S:554 E:563 ||| JJ
utility  ||| S:563 E:571 ||| NN
and  ||| S:571 E:575 ||| CC
accuracy  ||| S:575 E:584 ||| NN
of  ||| S:584 E:587 ||| IN
different  ||| S:587 E:597 ||| JJ
diagnostic  ||| S:597 E:608 ||| JJ
tests  ||| S:608 E:614 ||| NNS
and  ||| S:614 E:618 ||| CC
procedures  ||| S:618 E:629 ||| NNS
for  ||| S:629 E:633 ||| IN
detection  ||| S:633 E:643 ||| NN
of  ||| S:643 E:646 ||| IN
Candida  ||| S:646 E:654 ||| NNP
infections ||| S:654 E:664 ||| NNS
.  ||| S:664 E:666 ||| .
Recommendations  ||| S:666 E:682 ||| NNS
about  ||| S:682 E:688 ||| IN
the  ||| S:688 E:692 ||| DT
microbiological  ||| S:692 E:708 ||| JJ
investigation  ||| S:708 E:722 ||| NN
and  ||| S:722 E:726 ||| CC
detection  ||| S:726 E:736 ||| NN
of  ||| S:736 E:739 ||| IN
candidaemia ||| S:739 E:750 ||| NN
,  ||| S:750 E:752 ||| ,
invasive  ||| S:752 E:761 ||| JJ
candidiasis ||| S:761 E:772 ||| NN
,  ||| S:772 E:774 ||| ,
chronic  ||| S:774 E:782 ||| JJ
disseminated  ||| S:782 E:795 ||| JJ
candidiasis ||| S:795 E:806 ||| NN
,  ||| S:806 E:808 ||| ,
and  ||| S:808 E:812 ||| CC
oropharyngeal ||| S:812 E:825 ||| NN
,  ||| S:825 E:827 ||| ,
oesophageal ||| S:827 E:838 ||| NN
,  ||| S:838 E:840 ||| ,
and  ||| S:840 E:844 ||| CC
vaginal  ||| S:844 E:852 ||| JJ
candidiasis  ||| S:852 E:864 ||| NN
were  ||| S:864 E:869 ||| VBD
included ||| S:869 E:877 ||| VBN
.  ||| S:877 E:879 ||| .
In  ||| S:879 E:882 ||| IN
addition ||| S:882 E:890 ||| NN
,  ||| S:890 E:892 ||| ,
remarks  ||| S:892 E:900 ||| NNS
about  ||| S:900 E:906 ||| IN
antifungal  ||| S:906 E:917 ||| JJ
susceptibility  ||| S:917 E:932 ||| JJ
testing  ||| S:932 E:940 ||| NN
and  ||| S:940 E:944 ||| CC
therapeutic  ||| S:944 E:956 ||| JJ
drug  ||| S:956 E:961 ||| NN
monitoring  ||| S:961 E:972 ||| NN
were  ||| S:972 E:977 ||| VBD
made ||| S:977 E:981 ||| VBN
.  ||| S:981 E:983 ||| .
